Imatinib clinical trials
Also written Gleevec, Glivec, STI571 and CGP 57148.
How each study uses imatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the imatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 10 May 2001 · GLEEVEC · NDA 021335 (FDA, Drugs@FDA)
- European Union
- 7 Nov 2001 · Glivec · EMEA/H/C/000406 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
386 studies that test it; most in 2002 (42)
| Year | Studies |
|---|---|
| 1993 | 1 |
| 1999 | 3 |
| 2000 | 10 |
| 2001 | 20 |
| 2002 | 42 |
| 2003 | 34 |
| 2004 | 42 |
| 2005 | 26 |
| 2006 | 32 |
| 2007 | 25 |
| 2008 | 16 |
| 2009 | 14 |
| 2010 | 10 |
| 2011 | 8 |
| 2012 | 11 |
| 2013 | 6 |
| 2014 | 12 |
| 2015 | 7 |
| 2016 | 7 |
| 2017 | 8 |
| 2018 | 7 |
| 2019 | 5 |
| 2020 | 14 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 5 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 70 · Other 317
Novartis Pharmaceuticals (45) · National Cancer Institute (NCI) (37) · M.D. Anderson Cancer Center (27) · Novartis (8) · Asan Medical Center (7) · Bristol-Myers Squibb (6) · University of Bologna (6) · Poitiers University Hospital (5)
Often tested with
Tested in the same studies.
Dasatinib (19) · Nilotinib (17) · Docetaxel (13) · Cytarabine (12) · Gemcitabine (9) · Capecitabine (6) · Cisplatin (6) · Everolimus (6)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 6 phase 3 studies under way
Imatinib is the comparator. A study of two new drugs counts under both.
- 2Ponatinib · Takeda, Gruppo Italiano Malattie EMatologiche dell'Adulto · next primary completion Sep 2027
- 1Radotinib · Il-Yang Pharm. Co., Ltd.
- 1Asciminib · Novartis Pharmaceuticals
- 1Blinatumomab · Gruppo Italiano Malattie EMatologiche dell'Adulto · next primary completion Sep 2027
- 1Embibatinib · Jiangsu Hansoh Pharmaceutical Co., Ltd. · next primary completion Jul 2029
Reaching primary completion within a year · 4
Studies that test imatinib.
- Dec 2026Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)Phase 1 · Columbia University
- May 2027Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant MelanomaPhase 2 · University of California, San Francisco
- Jun 2027Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated MalariaPhase 2 · Victoria Biomedical Research Institute
- Oct 2027KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)Phase 2 · Kumquat Biosciences Inc.
Studies
Open first, then newest update. How each study uses imatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 387
- Asciminib Roll-over StudyRecruitingPhase 4Novartis PharmaceuticalsNCT04877522Written as Imatinib
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingPhase 3UMC UtrechtNCT02735707Written as Imatinib
- Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 DeficiencyRecruitingPhase 1National Cancer Institute (NCI)NCT06090669Written as imatinib
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT06124157Written as Imatinib
- A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)RecruitingPhase 3GlaxoSmithKlineNCT07585266Written as Imatinib
- Imatinib TDM in GISTRecruitingPhase 2Reema A. PatelNCT05493215Written as Imatinib
- Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant MelanomaRecruitingPhase 2University of California, San FranciscoNCT04598009Written as Imatinib
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic LeukaemiaRecruitingPhase 3Mats HeymanNCT04307576Written as Imatinib
- KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)RecruitingPhase 2Kumquat Biosciences Inc.NCT07406633Written as Imatinib (Gleevec)
- Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar PustulosisNot yet recruitingPhase 3Second Affiliated Hospital, Zhejiang University, School of MedicineNCT07530367Written as Imatinib
- Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated MalariaRecruitingPhase 2Victoria Biomedical Research InstituteNCT07559370Written as Artemether Lumefantrine and Imatinib Mesylate
- Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal TumorRecruitingPhase 1University of California, San DiegoNCT07171203Written as Imatinib
- Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)RecruitingPhase 1Columbia UniversityNCT06889168Written as Imatimib Mesylate
- 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High RiskRecruitingPhase 2Asan Medical CenterNCT05385549Written as Imatinib Mesylate
- Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)RecruitingNot applicableVastra Gotaland RegionNCT05722795Written as Imatinib 400 MG Oral Tablet
- Imatinib and Trametinib for KRAS-mutated Solid TumorRecruitingPhase 1China Medical University HospitalNCT06962254Written as Imatinib
- Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCTRecruitingPhase 2Goethe UniversityNCT06061094Written as Imatinib
- Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic DiseaseRecruitingPhase 4Wei ZhaoNCT03844360Written as Imatinib
- Precision Cancer Therapy in Rare CancersRecruitingPhase 2Oslo University HospitalNCT06119789Written as Imatinib
- PLATFORM Study of Precision Medicine for Rare TumorsRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT04423185Written as Imatinib 400 MG
See all 387 studies that test imatinib →
Given beside what is tested · 56 — imatinib is usual care or a partner of the new treatment
- A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingPhase 1Kura Oncology, Inc.NCT06655246Written as imatinib mesylate
- Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationRecruitingPhase 2Medical College of WisconsinNCT04838041Written as Imatinib
- Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CMLNot yet recruitingPhase 2The University of Hong KongNCT07493408Written as Imatinib
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingPhase 2Peking University Shenzhen HospitalNCT06692491Written as Imatinib
- A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young AdultsRecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT02611492Written as Imatinib
- Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic SyndromeActive, not recruitingPhase 2National Institutes of Health Clinical Center (CC)NCT00044304Written as Imatinib Mesylate
- A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard TreatmentsActive, not recruitingPhase 2Centre Leon BerardNCT05152472Written as Imatinib 400 MG
- Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination TherapyActive, not recruitingPhase 2Obafemi Awolowo UniversityNCT07022743Written as Imatinib
- Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual DiseaseActive, not recruitingPhase 2ECOG-ACRIN Cancer Research GroupNCT03516279Written as Imatinib Mesylate
- Frontline Asciminib Combination in Chronic Phase CMLActive, not recruitingPhase 2University of JenaNCT03906292Written as Imatinib
- Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CMLTerminatedPhase 3Sarit AssoulineNCT05413915Written as Imatinib
- A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)Active, not recruitingPhase 1Taiho Pharmaceutical Co., Ltd.NCT05245968Written as Imatinib
- Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid LeukemiaActive, not recruitingPhase 2SWOG Cancer Research NetworkNCT03654768Written as Imatinib
- Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified TreatmentCompletedPhase 3Goethe UniversityNCT02881086Written as Imatinib
- MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)Active, not recruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT01991379Written as Imatinib Mesylate (Gleevec®; STI571; NSC #716051)
- A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mgCompletedPhase 1Inhibikase TherapeuticsNCT05623774Written as Imatinib Mesylate
- ALL Adult Consortium Trial: Adult ALL TrialCompletedPhase 2Dana-Farber Cancer InstituteNCT00476190Written as Imatinib
- Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase InhibitorsTerminatedPhase 1M.D. Anderson Cancer CenterNCT01751425Written as Imatinib Mesylate
- A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GISTCompletedPhase 2Astex Pharmaceuticals, Inc.NCT01294202Written as AT13387 and Imatinib
- A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid TumorCompletedPhase 1/2Hyo Song KimNCT03802084Written as vactosertib/imatinib combination
Showing 20 of 56.
As the comparator · 34 — what is tested is compared with imatinib
- A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPNot yet recruitingPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07885293Written as Imatinib
- Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host DiseaseRecruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06682169Written as Imatinib
- A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseNot yet recruitingPhase 4Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT05367765Written as Imatinib
- Study in Adult Ph-positive ALLNot yet recruitingPhase 2Cardiff UniversityNCT04688983Written as Imatinib
- Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)Active, not recruitingPhase 3Il-Yang Pharm. Co., Ltd.NCT03722420Written as Imatinib
- A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPActive, not recruitingPhase 3Novartis PharmaceuticalsNCT04971226Written as Imatinib
- A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic LeukemiaActive, not recruitingPhase 3TakedaNCT03589326Written as Imatinib
- A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)CompletedPhase 3Incyte CorporationNCT03112603Written as Imatinib
- Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALLTerminatedPhase 4Institute of Hematology & Blood Diseases Hospital, ChinaNCT05071482Written as Imatinib
- Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALLActive, not recruitingPhase 3Gruppo Italiano Malattie EMatologiche dell'AdultoNCT04722848Written as Chemotherapy + Imatinib
- Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)WithdrawnPhase 2MedPacto, Inc.NCT06219733Written as Imatinib
- Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)TerminatedPhase 3AB ScienceNCT00812240Written as Imatinib
- A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedPhase 3PfizerNCT02130557Written as Imatinib
- A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic PhaseCompletedPhase 3Novartis PharmaceuticalsNCT02272777Written as Imatinib
- Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CMLCompletedPhase 3PfizerNCT00574873Written as imatinib
- Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML PatientsStatus unknownPhase 3First Affiliated Hospital of Harbin Medical UniversityNCT03515018Written as Imatinib
- Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid LeukaemiaCompletedPhase 3Newcastle UniversityNCT01460693Written as Imatinib
- The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CMLCompletedPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT02204644Written as Imatinib 400mg qd
- Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid LeukemiaCompletedPhase 2Norwegian University of Science and TechnologyNCT00852566Written as Imatinib
- A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid LeukemiaCompletedPhase 3Bristol-Myers SquibbNCT00481247Written as Imatinib
Showing 20 of 34.
What changed recently
From the registry's own updates since Oct 17, 2026.
Codes
What other systems call imatinib · ClinicalTrials.gg INT006552
- MeSH (NLM) D000068877Imatinib MesylateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) BKJ8M8G5HIIMATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 282388Confirmed FDA, Wikidata
- Wikidata Q177094imatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62035ImatinibOne source FDA
- DrugBank DB00619One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068877 | Imatinib Mesylate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | BKJ8M8G5HI | IMATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 282388 | — | Confirmed FDA, Wikidata |
| Wikidata | Q177094 | imatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62035 | Imatinib | One source FDA |
| DrugBank | DB00619 | — | One source Wikidata |
Also registered as imatinib mesylate (UNII 8A1O1M485B · RxNorm 284924).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.